BYSI Form 4: Decheng Capital reports sales, updates ownership
Rhea-AI Filing Summary
BeyondSpring Inc. (BYSI): Decheng Capital-affiliated reporting persons disclosed open-market sales of ordinary shares. On 10/03, 600 shares were sold at $1.76 (weighted average range $1.73–$1.79); on 10/06, 17,500 shares at $1.78 (range $1.73–$1.7879); and on 10/07, 2,100 shares at $1.79 (range $1.74–$1.80). The filing is made by more than one reporting person, noted as Director and 10% Owner.
Following these transactions, indirect beneficial holdings were reported as 1,817,896 shares by Decheng Capital China Life Sciences USD Fund III, L.P., 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II, L.P., and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP.
Positive
- None.
Negative
- None.
Insights
Routine insider sales; multi-entity indirect holdings disclosed.
The filing lists open-market sales by entities affiliated with Decheng Capital, identified as a Director and 10% Owner. Transactions on 10/03, 10/06, and 10/07 were executed at weighted average prices of $1.76, $1.78, and $1.79, with detailed price ranges provided.
Post-transaction indirect beneficial ownership is reported separately across funds: Fund III at 1,817,896 shares, Fund II at 1,617,409 shares, and the Global Healthcare Fund at 891,734 shares. The filing notes standard disclaimers regarding beneficial ownership through general partners and a manager.
Actual market impact depends on holder decisions and trading volumes; the filing permits no conclusions beyond the disclosed sales and updated holdings.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 2,100 | $1.79 | $4K |
| Sale | Ordinary Shares | 17,500 | $1.78 | $31K |
| Sale | Ordinary Shares | 600 | $1.76 | $1K |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.7879 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.74 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
